title: Anti-ischemic effect of a novel cardioprotective agent, JTV519, is mediated through specific activation of delta-isoform of protein kinase C in rat ventricular myocardium.
abstract: BACKGROUND
  A new 1,4-benzothiazepine derivative, JTV519, has a strong protective effect against Ca(2+) overload-induced myocardial injury. We investigated the effect of JTV519 on ischemia/reperfusion injury in isolated rat hearts.
  
  
  RESULTS
  At 30 minutes of reperfusion after 30-minute global ischemia, the percent recovery of left ventricular developed pressure was improved, and the creatine phosphokinase and lactate dehydrogenase leakage was reduced in a concentration-dependent manner when JTV519 was administered in the coronary perfusate both at 5 minutes before the induction of ischemia and at the time of reperfusion. The myocardial protective effect of JTV519 was completely blocked by pretreatment of the heart with GF109203X, a specific protein kinase C (PKC) inhibitor. In contrast, the effect of JTV519 was not affected by alpha(1)-, A(1)-, and B(2)-receptor blockers that couple with PKC in the cardiomyocyte. Both immunofluorescence images and immunoblots of JTV519-treated left ventricular myocardium and isolated ventricular myocytes demonstrated that this agent induced concentration-dependent translocation of the delta-isoform but not the other isoforms of PKC to the plasma membrane.
  
  
  CONCLUSIONS
  The mechanism of cardioprotection by JTV519 against ischemia/reperfusion injury involves isozyme-specific PKC activation through a receptor-independent mechanism. This agent may provide a novel pharmacological approach for the treatment of patients with acute coronary diseases via a subcellular mechanism mimicking ischemic preconditioning.
authors.affiliation: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Inagaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kihara
authors.forename: W
authors.initials: W
authors.lastname: Hayashida
authors.forename: T
authors.initials: T
authors.lastname: Izumi
authors.forename: Y
authors.initials: Y
authors.lastname: Iwanaga
authors.forename: T
authors.initials: T
authors.lastname: Yoneda
authors.forename: Y
authors.initials: Y
authors.lastname: Takeuchi
authors.forename: K
authors.initials: K
authors.lastname: Suyama
authors.forename: E
authors.initials: E
authors.lastname: Muso
authors.forename: S
authors.initials: S
authors.lastname: Sasayama
mesh_terms: D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004789:Enzyme Activation; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000378:metabolism*; D017202:Myocardial Ischemia / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D009206:Myocardium / Q000201:enzymology*; D011493:Protein Kinase C / Q000378:metabolism*; D051745:Protein Kinase C-delta; D051381:Rats; D013841:Thiazepines / Q000494:pharmacology*; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D002121:Calcium Channel Blockers; D007527:Isoenzymes; D013841:Thiazepines; C109183:K201 compound; C497260:Prkcd protein, rat; D011493:Protein Kinase C; D051745:Protein Kinase C-delta